« Back
Home /
Ponatinib

Ponatinib

€72.00

Excl. VAT

Item no.	HY-12047-10mM
Manufacturer	MedChem Express
CASRN	943319-70-8
Amount	10 mM/1 mL
Category	Oncology Cardiovascular Research Thrombosis & Hemostasis Inhibitors & Compound Libraries Small Molecules By Organ Heart & Blood Cancer
Type	Inhibitors
Clone	N/A
Specific against	other
Purity	99.43
Formula	C29H27F3N6O
Citations	Acta Pharm Sin B. 2023 Oct;13(10):4253-4272. Acta Pharmacol Sin. 2021 Jan;42(1):108-114. Biochem Pharmacol. 2021 Jul 30;114710. Biomolecules. 2022 Jun 11;12(6):819. Cancer Discov. 2021 Jan;11(1):126-141. Clin Chim Acta. 2018 May;480:180-185. Eur J Pharmacol. 2020 Dec 15;889:173292. Exp Hematol. 2014 May;42(5):369-379.e3. Fundam Clin Pharmacol. 2021 Feb 1. Harvard Medical School LINCS LIBRARY J Ethnopharmacol. 2023 Dec 28, 117669. J Ethnopharmacol. 2023 Feb 17;116275. J Med Chem. 2019 May 23;62(10):5006-5024. Leuk Res. 2016 Jun;45:24-32. Neurosci Bull. 2020 Mar;36(3):263-276. Pharmaceuticals. 2022, 15(9), 1073. Pharmacogn Mag. 2023 Jul 20. PLoS One. 2021 Sep 30;16(9):e0258140. PLoS One. 2022 Feb 14;17(2):e0263822. Research Square Preprint. 2021 May. Research Square Print. 2023 Mar 23. Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. Target Oncol. 2020 Oct;15(5):659-671. Technical University of Munich. 24.01.2018. Biomaterials. 16 September 2022. [1]O'Hare T, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell, 2009, 16(5), 401-412. [2]Gozgit JM, et al. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol Cancer Ther, 2011, 10(6), 1028-1035. [3]Uchida T, et al. Hes1 upregulation contributes to the development of FIP1L1-PDGRA-positive leukemia in blast crisis. Exp Hematol. 2014 May;42(5):369-379.e3.
Smiles	CC1=C(C=C(C=C1)C(NC2=CC(C(F)(F)F)=C(C=C2)CN3CCN(CC3)C)=O)C#CC4=CN=C5N4N=CC=C5
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	AP24534
Available
Product Description	Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively[1].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
Molecular Weight	532.56
Clinical Information	Launched
Solubility	1M HCl : 50 mg/mL (ultrasonic; adjust pH to 1 with HCl)\|DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)
Isoform	FGFR1; PDGFRα; VEGFR2/KDR/Flk-1
Pathway	Autophagy; Protein Tyrosine Kinase/RTK
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-12047-10mM-safety-datasheet.pdf